Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine‐based therapy with or without bevacizumab

Pant, Shubham; Martin, Ludmila K.; Geyer, Susan; Wei, Lai; Van Loon, Katherine; Sommovilla, Nilli; Zalupski, Mark; Iyer, Renuka; Fogelman, David; Ko, Andrew H.; Bekaii‐saab, Tanios

research article

oai:deepblue.lib.umich.edu:2027.42/107373

Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine‐based therapy with or without bevacizumab

Authors: Shubham Pant
Ludmila K. Martin
Susan Geyer
Lai Wei
Katherine Van Loon
Nilli Sommovilla
Mark Zalupski
Renuka Iyer
David Fogelman
Andrew H. Ko
Tanios Bekaii‐saab
Publication date: 15 June 2014
Publisher: John Wiley & Sons
Doi

Abstract

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/107373/1/cncr28648.pd

Similar works

Full text

Deep Blue Documents

oai:deepblue.lib.umich.edu:202...

Last time updated on 20/12/2016

This paper was published in Deep Blue Documents.

Having an issue?

Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.